𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Is FOXP3 a bona fide marker for human regulatory T cells?

✍ Scribed by Maria-Grazia Roncarolo; Silvia Gregori

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
132 KB
Volume
38
Category
Article
ISSN
0014-2980

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

FOXP3 is a specific marker for naturally occurring regulatory T cells (nTreg). FOXP3 expression is correlated with development and function of nTreg. Recent evidence suggests that, upon activation, human effector T (Teff) cells and type 1 regulatory T (Tr1) cells can express FOXP3, albeit transiently. While the role of transient FOXP3 expression in Teff cells is poorly understood, it is becoming clear that it does not correlate with suppressor function. Furthermore, FOXP3‐independent mechanisms, mediated by IL‐10, contribute to the induction and suppressor functions of Tr1 cells.

See accompanying commentary: http://dx.doi.org/10.1002/eji.200838147

πŸ“œ SIMILAR VOLUMES

c-Rel is crucial for the induction of Fo
c-Rel is crucial for the induction of Foxp3+ regulatory CD4+ T cells but not TH17 cells
✍ Alexander Visekruna; Magdalena Huber; Anne Hellhund; Evita Bothur; Katharina Rei πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 228 KB πŸ‘ 1 views

## Abstract The NF‐κB/Rel family member c‐Rel was described to be required for the development of T~H~1 responses. However, the role of c‐Rel in the differentiation of T~H~17 and regulatory CD4^+^Foxp3^+^ T cells (Treg) remains obscure. Here, we show that in the absence of c‐Rel, __in vitro__ diffe

NKG2A is a marker for acquisition of reg
NKG2A is a marker for acquisition of regulatory function by human CD8+ T cells activated with anti-CD3 antibody
✍ Vitaly Ablamunits; Octavian Henegariu; Paula Preston-Hurlburt; Kevan C. Herold πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 435 KB πŸ‘ 1 views

## Abstract Treatment with anti‐CD3 mAb modulates immune responses that cause type 1 diabetes and other diseases. CD8^+^ Tregs can be induced in vitro and in vivo by mAb. However, 1/3 of patients do not respond to drug therapy and in an equal proportion, anti‐CD3 mAb does not induce Tregs in vitro.